New AI method improves Gene Splicing Prediction
Scientists from deCODE genetics, a subsidiary of Amgen, and the University of Iceland have developed a new artificial intelligence method that enhances the accuracy of predicting RNA splicing, a fundamental process in gene regulation.
A rare missense variant that protects against asthma
Scientists at deCODE genetics, a subsidiary of Amgen, and collaborators have published a study in Journal of Allergy and Clinical Immunology reporting a rare missense variant in STAT6 that protects against asthma.
New Study Explores the Role of BMI in Disease Risk
A new study from deCODE genetics/Amgen highlights the importance of BMI in the pathogenesis of disease, suggesting that reducing BMI alone could lower the risk of several diseases.
Discovery of cancer risk associations for six novel genes
Scientists at deCODE genetics/Amgen, and their collaborators have discovered six novel genes with rare germline variants that associate with cancer risk. The findings are published today in Nature Genetics under the title “Gene-based burden tests of rare germline variants identify six cancer susceptibility genes.”
UNIQUE EXPERTISE
Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using our unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.
UNIQUE CAPABILITIES
We operate the most productive human gene discovery engine in the world, employing our discoveries to identify genetic variations associated with human disease.
OUR PUBLICATIONS
We regularly publish our discoveries in major, peer-reviewed journals, enabling others to further validate and expand upon our findings.